Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.55 |
| ▸ | CDC25B | P30305 | 1/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | FYN | P06241 | 2/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.46 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68192 | 0.76 | FYN (0.48) | FYNTNIKMAPT | |
| SCHEMBL66548 | 0.76 | FYN (0.50) | KDM4EFYNABCB1TNIK | |
| SCHEMBL84550 | 0.75 | PTGS2 (0.53) | FYNTNIK | |
| SCHEMBL23743163 | 0.72 | CYP1B1 (0.74) | CYP1B1CYP1A1KDM4EARCYP19A1 | |
| SCHEMBL28329081 | 0.72 | NFE2L2 (0.62) | CYP1B1CYP1A1KDM4EARRAB9A | |
| SCHEMBL28329083 | 0.72 | NFE2L2 (0.62) | CYP1B1CYP1A1KDM4EARRAB9A | |
| SCHEMBL6198667 | 0.71 | ALDH1A1 (0.72) | CYP1B1CYP1A1KDM4ERAB9AALDH1A1 | |
| SCHEMBL85078 | 0.70 | MAPK14 (0.43) | KDM4EFYNALDH1A1MEN1KMT2A | |
| SCHEMBL7532567 | 0.70 | RAB9A (0.73) | CYP1B1CYP1A1KDM4EARCYP19A1 | |
| Hydrochloric Acid SCHEMBL6197627 | 0.69 | ALDH1A1 (0.58) | CDC25ACDC25BCYP1B1CYP1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| CN-102015686-B | Novel heterocyclic compounds and uses therof | NOVARTIS AG | 2014-07-02 | — | — | CN | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| CN-102015686-A | Novel heterocyclic compounds and uses therof | NOVARTIS AG | 2011-04-13 | — | — | CN | disclosed |
| EP-2274300-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | CDC25A 813/4885CDC25B 588/4885CYP1B1 3928/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | CDC25A 395/4885CDC25B 356/4885CYP1B1 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.